DEF 14A: Beyond Air Seeks Stockholder Approval for Key Proposals at 2025 Annual Meeting

Beyond Air is convening its 2025 annual meeting to vote on director elections, auditor ratification, equity incentive plan amendments, executive compensation, and an increase in authorized common stock.

Summary

• Beyond Air, Inc. is holding its 2025 Annual Meeting of Stockholders on November 22, 2024, to vote on several key proposals.
• The proposals include electing six directors, ratifying the appointment of Marcum LLP as the independent auditor, and approving amendments to the 2013 Equity Incentive Plan.
• Stockholders will also vote on an advisory basis on executive compensation and a proposal to increase the number of authorized shares of common stock from 100,000,000 to 500,000,000.
• Additionally, they will vote on authorizing the issuance of shares underlying warrants related to a Securities Purchase Agreement dated September 26, 2024, and potentially adjourning the meeting to solicit further votes.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining proposals for stockholder vote. While it highlights potential benefits, it also acknowledges risks and potential dilution, resulting in a neutral to slightly positive sentiment.

Positives

• The proposed increase in authorized shares provides flexibility for future financings, acquisitions, and strategic partnerships.
• Approval of the equity incentive plan amendment is expected to help attract and retain talented employees, consultants, and directors.
• The Board of Directors is actively engaged in overseeing the company's risk exposure and corporate governance.

Negatives

• The potential issuance of a large number of shares underlying warrants could dilute existing stockholders' ownership.
• If the proposals are not approved, the company may face limitations in its ability to raise capital and incentivize employees.
• The company has a history of losses, as indicated by the net loss figures in the Pay Versus Performance section.

Risks

• Failure to obtain stockholder approval for the proposals could limit the company's financial flexibility and strategic options.
• The market price of the common stock could decline due to the issuance or resale of shares upon exercise of the warrants.
• The company's reliance on equity incentive awards may be impacted if the equity incentive plan amendment is not approved.

Future Outlook

The company anticipates that the proposed 3,000,000 share increase will provide a pool of shares that is expected to last for approximately 12 months.

Management Comments

• The Board of Directors believes that the increase in our authorized shares of Common Stock is in the best interests of the Company and unanimously recommends approval by the stockholders.
• The Board of Directors believes that the Seventh Amended Plan will be sufficient to achieve our recruiting, retention and incentive goals for the next twelve months and will be essential to our future success.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but it does mention that the company competes with other medical device technology companies in hiring and retaining top talent.

Comparison to Industry Standards

• The document does not provide specific details on how this announcement relates to global benchmarks.
• The document does not provide specific details on comparable companies, projects, and results.

Related Party Transactions

• On September 27, 2024, the Company issued 9,886,633 warrants with a strike price of $0.3793 to Robert Carey upon signature of a binding term sheet whereby Mr. Carey will loan $7,500,000 to the Company.
• On that same say, the Company issued 3,295,544 warrants with a strike price of $0.3793 to Steve Lisi upon signature of a binding term sheet whereby Mr. Lisi will loan $2,500,000 to the Company.

Stakeholder Impact

• Approval of the proposals could benefit shareholders by providing the company with greater financial flexibility and strategic options.
• Failure to approve the proposals could negatively impact shareholders by limiting the company's ability to raise capital and incentivize employees.
• Employees and consultants may be impacted by the approval or disapproval of the equity incentive plan amendment.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will file the Certificate of Amendment with the Secretary of State of the State of Delaware if Proposal 5 is approved.
• The company will file a registration statement covering the resale of the Registrable Securities by the investors on October 25, 2024 and are required to have such Registration Statement declared effective.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Equity Incentive Plan, Common Stock, Warrants, Directors, Auditor, Compensation, Beyond Air